SARS-CoV-2 RBD dimers elicit response comparable to VLPs in mice

Abstract We report the direct comparison of monomeric, dimeric and trimeric RBD protein subunit vaccines to a virus-like particle (VLP) displaying RBD. After two and three doses, a RBD dimer and trimer elicited antibody levels in mice comparable to an RBD-VLP. Furthermore, an Omicron (BA.1) RBD hetero-dimer induced neutralizing activity similar to the RBD-VLP. A RBD hetero-dimer and RBD-VLP also shows comparable breadth to other SARS-CoV-2 variants-of-concern (VOCs).

[1]  D. Montefiori,et al.  A Bivalent Omicron-Containing Booster Vaccine against Covid-19 , 2022, The New England journal of medicine.

[2]  S. Khoshnood,et al.  A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19 , 2022, Frontiers in Microbiology.

[3]  D. Vashdi,et al.  How to boost the boosters? A survey-experiment on the effectiveness of different policies aimed at enhancing acceptance of a “Seasonal” vaccination against COVID-19 , 2022, Israel Journal of Health Policy Research.

[4]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[5]  B. Pulendran,et al.  Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice , 2022, NPJ vaccines.

[6]  D. Goldblatt.  SARS-CoV-2: from herd immunity to hybrid immunity , 2022, Nature Reviews Immunology.

[7]  Guizhen Wu,et al.  Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2 , 2022, Cell.

[8]  Neil C. Dalvie,et al.  SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques , 2022, Science advances.

[9]  Y. Kreiss,et al.  Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection , 2021, medRxiv.

[10]  C. Camargo,et al.  COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly , 2021, Vaccines.

[11]  Y. Kreiss,et al.  Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.

[12]  Y. Bi,et al.  The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice , 2021, Signal Transduction and Targeted Therapy.

[13]  Gengfu Xiao,et al.  RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates , 2021, Cell discovery.

[14]  Laura E. Crowell,et al.  Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice , 2021, Proceedings of the National Academy of Sciences.

[15]  Lisa E. Gralinski,et al.  SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung , 2021, Nature Communications.

[16]  Yan Liu,et al.  Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials , 2021, The Lancet Infectious Diseases.

[17]  G. Gao,et al.  A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates , 2021, bioRxiv.

[18]  Lisa E. Gralinski,et al.  Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Walls, Fiala et al. , 2020 .

[19]  P. Hotez,et al.  Developing a low-cost and accessible COVID-19 vaccine for global health , 2020, PLoS neglected tropical diseases.

[20]  Neil C. Dalvie,et al.  The yeast stands alone: the future of protein biologic production. , 2018, Current opinion in biotechnology.

[21]  H. Kim.  Yeast as an expression system for producing virus‐like particles: what factors do we need to consider? , 2017, Letters in applied microbiology.

[22]  Nikolaos Scarmeas,et al.  The good, bad, and ugly? , 2012, Neurology.

[23]  M. Nussenzweig,et al.  One sentence summary: Nanoparticle strategy for pan-sarbecovirus vaccine Keywords: neutralizing antibodies, receptor-binding domain, sarbecoviruses, vaccine, zoonotic coronaviruses 125-character summary for online ToC: Immunizing with nanoparticles displaying diverse coronavirus RBDs elicits cross-r , 2020 .